logo
Man Adopts a 'Fitness is Fun' Mindset and Loses 85 Pounds Playing This Trendy Game

Man Adopts a 'Fitness is Fun' Mindset and Loses 85 Pounds Playing This Trendy Game

Yahoo4 hours ago
For Ethan Noblesala, 32, a diagnosis of prediabetes and a blunt prediction from his doctor in November, 2023, motivated him to improve his health.
"My doctor told me, 'If you don't change your lifestyle, you're going down a route that's leading to more surgeries, more operations and more medication,'" Noblesala tells TODAY.
He says he was at his healthiest during college, but as he built his career as an entrepreneur, he neglected his health and focused on building his businesses. 'As I started that corporate lifestyle, I was slowly gaining weight,' he says.
To foster business growth and connections, he was spending a lot of time at happy hours. He was lucky if he slept four hours a night. Uber Eats was the cornerstone of his diet. Exercise or even spending any time outside was practically non-existent. And his habits only got worse during COVID. His weight climbed to 235 pounds, which was a strain on his 5-foot, 6-inch frame.
'Even though I was running a successful business with my co-founder, I decided to take a leave to really focus on what was most important to me — my health,' he says. That attention to his health worked. He lost 85 pounds, and he says he feels 10 years younger. Here's how he did it.
Noblesala has a background in finance, so he's motivated by numbers. He honed in on them to make changes, tracking his protein, fiber and calories.
He discovered that when he ate mainly protein and fiber-dense meals, he felt satiated even when he was only eating 1,500 calories a day: 'Your body needs nutrition, but I never felt like I was starving myself or restricting myself.'
He built on small goals and habit changes:
Drinking a glass of water every day: 'I was 85 pounds heavier. I wasn't going to go out and run five miles, or try any of the crazy trends I see online. This was something I could do.'
Shopping for groceries and checking the nutrition labels for protein, fiber and calories instead of eating out — and overeating — five times a week.
Having a go-to, high-fiber, low-calorie meal that he liked to eat: Shirataki noodles with chicken breast in a low-fat buffalo sauce.
Finding healthier swaps for foods he likes, such as Costco chicken nuggets instead of McDonald's: 'I found it exciting to make these new discoveries. It's something I love to do.'
Noblesala grew up playing sports and loved how they kept him active while also being a way to connect with others. He'd often ask his friends if they wanted to play basketball, tennis or something else together. 'Through tennis, I discovered pickleball. That was the hook for me in terms of living a healthier and active lifestyle. I've become a pickleball fanatic,' he says.
In December 2023, he joined Life Time. 'One thing I appreciate there is the community. I get to play pickleball, my favorite sport. Some people say going to the gym is a chore, but I'm excited to go."
"There are endorphins you get from exercising, from being around others and from having that community," he says. "In the past, going to the gym was a solo grind, and I had to force myself to go. Now, it's not a chore. It's part of my lifestyle."
Having friends at the gym and at pickleball builds accountability for him, too. 'My friends will say, 'Ethan, I'll see you tomorrow.' And, of course, then I go after work. They're expecting me,' he says.
He has also joined some running clubs, such as Pitch & Run, and now he's working toward an ambitious goal — running the New York City marathon in November. He earned the opportunity to participate through his alma mater, Chaminade High School in Long Island. 'I'm nervous for the marathon because I know it's a daunting mental task. I'm focusing on the interval training and the strength training,' he says.
Noblesala recognizes now how his lack of sleep was making his health worse: 'Your body needs to recover. I'm averaging six and a half to seven and a half hours of sleep a night now, and I definitely feel it when I don't get seven hours of sleep.'
He's also careful about balancing his workouts with rest. He finds fitness data so valuable that he wears an Apple watch, a Whoop tracker and an Oura ring. After a day where he ran seven miles and played two hours of pickleball, he saw that his Whoop told him to take it lighter the next day.
'You can make these informed decisions with technology. It was harder to do this 10 years ago,' he says.
Now that Noblesala is 85 pounds lighter and his life is centered around healthy living, he has no intention of returning to his old habits. In fact, it inspired Ethan's new company WeFit Labs, which is a gamified social fitness app designed to help motivate people to move together.
If you're looking for a fitness community, join our Start TODAY walking club on Facebook and connect live with members and experts during coaching calls on the Start TODAY app!
This article was originally published on TODAY.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment

Yahoo

time39 minutes ago

  • Yahoo

Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment

Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously enrolled in ARCH, CANYON, GRAND CANYON, or DUNE trials. Sevasemten maintained a favorable safety profile over up to 3 years of treatment. For Duchenne muscular dystrophy, Edgewise announced encouraging topline data from its Phase 2 LYNX and FOX trials. A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Sevasemten is an orally administered and first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies like Becker and Duchenne. Becker muscular dystrophy is a rare, genetic, debilitating, and degenerative neuromuscular disorder primarily affecting males, with no currently approved therapies. Duchenne muscular dystrophy is a severe degenerative muscle disorder, the most common type of muscular dystrophy, with a median life expectancy of around 30 years. Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas
Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Yahoo

timean hour ago

  • Yahoo

Abbott, Beta Bionics Partner to Integrate Dual Glucose-Ketone Sensor with iLet Bionic Pancreas

Abbott Laboratories (NYSE:ABT) is one of the high profit margin stocks to buy now. On June 19, Beta Bionics Inc. (NASDAQ:BBNX) announced its plan to integrate its iLet Bionic Pancreas automated insulin delivery/AID system with Abbott's future dual glucose-ketone sensor in the US. The collaboration aims to enhance real-time decision-making support for individuals with diabetes. The iLet Bionic Pancreas received FDA clearance in May 2023 and is distinguished as the first and only AID system that autonomously makes 100% of insulin dosing decisions. This eliminates the need for carb counting or manual insulin correction calculations for users, though they still need to be 'carb aware.' The system currently supports Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor, and the new agreement deepens the ongoing partnership between Beta Bionics and Abbott. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. The new dual sensor is currently under development and is built on the same form factor as Abbott's FreeStyle Libre 3 Plus and will continuously monitor both glucose and ketone levels. Ketone monitoring is a crucial advancement as it can help detect early signs of diabetic ketoacidosis, which is a serious complication of diabetes. Abbott's dual glucose-ketone sensor has received FDA breakthrough device designation. Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells health care products. Beta Bionics Inc. (NASDAQ:BBNX) is a commercial-stage medical device company. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

Yahoo

time2 hours ago

  • Yahoo

BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies

BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store